In vitro anti‐tumour activity of anti‐CD80 and anti‐CD86 immunotoxins containing type 1 ribosome‐inactivating proteins

No abstract is available for this paper.

• Publication year

  2000

• Venue

  British Journal of Haematology

• Publication date

  2000-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.2000.02193.xPMID 10971392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotoxins for targeted cancer therapy

  2006cited by this paper
• Evaluation of immunotoxins containing single‐chain ribosome‐inactivating proteins and an anti‐CD22 monoclonal antibody (OM124): in vitro and in vivo studies

  1998cited by this paper
• Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin.

  1998cited by this paper
• Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow

  1998cited by this paper
• The role of B7 co‐stimulation in activation and differentiation ofCD4+and CD8+T cells

  1998cited by this paper
• Role of caspases in immunotoxin-induced apoptosis of cancer cells.

  1998cited by this paper
• CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

  1997cited by this paper
• Expression of B7-2 (CD86) molecules by Reed–Sternberg cells of Hodgkin’s disease

  1997cited by this paper
• New ribosome-inactivating proteins with polynucleotide:adenosine glycosidase and antiviral activities from Basella rubra L. and Bougainvillea spectabilis Willd.

  1997cited by this paper
• Polynucleotide:adenosine glycosidase activity of ribosome-inactivating proteins: effect on DNA, RNA and poly(A).

  1997cited by this paper
• Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.

  1997cited by this paper
• B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.

  1997cited by this paper
• Induction of apoptosis by ribosome‐inactivating proteins and related immunotoxins

  1996cited by this paper
• CD28/B7 system of T cell costimulation.

  1996cited by this paper
• Immunotoxins: an update.

  1996cited by this paper
• Pathophysiology of Hodgkin's disease: functional and molecular aspects.

  1996cited by this paper
• B7-mediated costimulation and the immune response.

  1996influential reference
• T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions.

  1995cited by this paper
• CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?

  1995cited by this paper
• Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation

  1994cited by this paper
• Ribosome-inactivating proteins from plants.

  1993cited by this paper
• Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

  1993cited by this paper
• B70 antigen is a second ligand for CTLA-4 and CD28

  1993cited by this paper
• Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation

  1992cited by this paper
• Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.

  1992cited by this paper
• B‐B10 (ANTI‐CD25)‐SAPORIN IMMUNOTOXIN—A POSSIBLE TOOL IN GRAFT‐VERSUS‐HOST DISEASE TREATMENT

  1992cited by this paper
• Ribosome inactivating proteins of plants.

  1991cited by this paper
• Large scale chromatographic purification of ribosome-in-activating proteins

  1987cited by this paper
• Leukocyte Typing II

  1986cited by this paper
• Synthesis of hemoglobin in a cell-free system. I. Properties of the complete system.

  1962cited by this paper
• Tissue sulfhydryl groups.

  1959cited by this paper
• TISSUE SULPHYDRYL GROUPS

  1959cited by this paper

• A Spectroscopic Study on Secondary Structure and Thermal Unfolding of the Plant Toxin Gelonin Confirms Some Typical Structural Characteristics and Unravels the Sequence of Thermal Unfolding Events

  2019cites this paper
• Bouganin, an Attractive Weapon for Immunotoxins

  2018cites this paper
• A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery

  2018cites this paper
• Pokeweed (Phytolacca americana L.) antiviral protein inhibits Zucchini yellow mosaic virus infection in a dose-dependent manner in squash plants

  2017cites this paper
• Hyperuricaemia, Xanthine Oxidoreductase and Ribosome-Inactivating Proteins from Plants: The Contributions of Fiorenzo Stirpe to Frontline Research

  2017cites this paper
• A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding

  2017cites this paper
• Clinical targeting recombinant immunotoxins for cancer therapy

  2017cites this paper
• Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells

  2017cites this paper
• DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

  2016cites this paper
• Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance

  2016cites this paper
• High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin

  2016cites this paper
• Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview

  2016cites this paper
• Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop

  2015cites this paper
• The thermal unfolding of the ribosome-inactivating protein saporin-S6 characterized by infrared spectroscopy.

  2015cites this paper
• Resistance of Cancer Cells to CTL-Mediated Immunotherapy

  2015cites this paper
• Human Leukocyte Antigen–Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer

  2015cites this paper
• Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy

  2014influential citation
• Antibody‐Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins

  2014cites this paper
• The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)

  2013cites this paper
• Differential inhibitory potencies and mechanisms of the type I ribosome inactivating protein marmorin on estrogen receptor (ER)-positive and ER-negative breast cancer cells.

  2013cites this paper
• Classic Immunotoxins with Plant or Microbial Toxins

  2013cites this paper
• The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

  2013cites this paper
• The Preclinical and Clinical Evaluation of VB 6-845 : An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

  2013cites this paper
• Saporin-S6: A Useful Tool in Cancer Therapy

  2013cites this paper
• Construction and Characterization of a CTLA-4-Targeted scFv–Melittin Fusion Protein as a Potential Immunosuppressive Agent for Organ Transplant

  2013cites this paper
• Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins

  2013cites this paper
• Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases

  2012cites this paper
• Recombinant Immunotoxins Containing Truncated Bacterial Toxins for the Treatment of Hematologic Malignancies

  2012cites this paper
• Evolving Therapies in Relapsed and Refractory Hodgkin Lymphoma

  2012cites this paper
• Preclinical Evaluation of VB6-845: An Anti-EpCAM Immunotoxin with Reduced Immunogenic Potential

  2012cites this paper
• Galiximab Signals B-NHL Cells and Inhibits the Activities of NF-κB–Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoimmunotherapeutic Drugs

  2012cites this paper
• Distinct cellular responses induced by saporin and a transferrin–saporin conjugate in two different human glioblastoma cell lines

  2012cites this paper
• Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases

  2011cites this paper
• Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy

  2011cites this paper
• Cloning and soluble expression of mature alpha-luffin from Luffa cylindrica and its antitumor activities in vitro.

  2010cites this paper
• ATG‐saporin‐S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells

  2009cites this paper
• Macromolecular crystallography: crystallisation and structural determination

  2009cites this paper
• Structure/function studies on two type 1 ribosome inactivating proteins: Bouganin and lychnin.

  2009cites this paper
• Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin

  2009cites this paper
• Atomic resolution (1.1 Å) structure of the ribosome‐inactivating protein PD‐L4 from Phytolacca dioica L. leaves

  2008cites this paper
• Targetable oncogenic pathways in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma

  2008cites this paper
• Characterization of highly toxic type 2 ribosome-inactivating proteins from Adenia lanceolata and Adenia stenodactyla (Passifloraceae).

  2007cites this paper
• Isolation and Characterization of Ribosome‐Inactivating Proteins from Cucurbitaceae

  2007cites this paper
• Conjugation of an anti–transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells

  2007cites this paper
• In vitro and in vivo toxicity of type 2 ribosome-inactivating proteins lanceolin and stenodactylin on glial and neuronal cells.

  2007cites this paper
• Immunotoxins: A Review of Their Use in Cancer Treatment

  2006cites this paper
• Ribosome-inactivating proteins in edible plants and purification and characterization of a new ribosome-inactivating protein from Cucurbita moschata.

  2006cites this paper
• Immunotoxins in the treatment of hematologic malignancies.

  2006cites this paper
• Immunotoxins in the treatment of refractory hairy cell leukemia.

  2006cites this paper
• Ribosome-inactivating proteins: progress and problems

  2006cites this paper
• Immunotoxins for targeted cancer therapy

  2006cites this paper
• Toxicity of xanthine oxidoreductase to malignant B lymphocytes.

  2005cites this paper
• Occupational sensitization to ribosome‐inactivating proteins in researchers

  2005cites this paper
• Effective tumor targeting: strategies for the delivery of Armed Antibodies.

  2005cites this paper
• Expression and characterisation in E. coli of mutant forms of saporin.

  2005cites this paper
• CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.

  2005cites this paper
• Ribosome-inactivating proteins and other lectins from Adenia (Passifloraceae).

  2005cites this paper
• CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma.

  2004cites this paper
• The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine

  2004cites this paper
• Immunotoxins and other conjugates: pre-clinical studies.

  2004cites this paper
• Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma.

  2004cites this paper
• Cytotoxicity and toxicity to animals and humans of ribosome-inactivating proteins.

  2004cites this paper
• A comparative study of the subcellular distribution of native and deglycosylated gelonin in rat liver and kidney.

  2004cites this paper
• CD22-directed monoclonal antibody therapy for lymphoma.

  2003cites this paper
• A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins

  2003cites this paper
• Immunotoxin therapy of hematologic malignancies.

  2003cites this paper
• Immunobiological treatments of hairy-cell leukaemia.

  2003cites this paper
• Epratuzumab: targeting B-cell malignancies through CD22.

  2003cites this paper
• Effect of monensin liposomes on the cytotoxicity of anti‐My9‐bR immunotoxin

  2003cites this paper
• A type-I ribosome-inactivating protein from Bougainvillea spectabilis Willd

  2002cites this paper
• Novel poly(ethylene glycol) derivatives for preparation of ribosome-inactivating protein conjugates.

  2002cites this paper
• Selective lesions of rabbit extraocular muscles injected with the anti-AChR immunotoxin saporin-mAb 73

  2002cites this paper
• HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma Cells

  2002cites this paper
• Anticorps CD80 pour utilisation en combinaison avec agents chemothérapeutiques pour le traitement de malignité de cellules B

  2002cites this paper
• Cancer Drug Discovery and Development

  2002cites this paper
• Cloning and expression of cDNA coding for bouganin.

  2002cites this paper
• Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model1

  2001cites this paper
• Variable Antibodies and Saporin: In Vitro Anti-CTLA-4 Single-Chain Fragment Immunotoxins Containing Recombinant

  2001cites this paper
• Immunotoxins for targeted cancer therapy.

  1998cites this paper